IsoRay, BrachySciences ink distribution deal

The Oxford, Conn.-based BrachySciences, a division of Biocompatibles International, has signed an agreement with IsoRay to distribute its Proxcelan Cesium-131 brachytherapy seeds.

"Management believes this distribution agreement will enable us to increase the sales of Cesium-131 within the prostate cancer therapy market. This supports our ongoing strategy of driving sales by adding an additional outside distribution channel to augment our current sales staff," said Dwight Babcock, IsoRay's chairman and CEO.

The Richland, Wash.-based IsoRay said it remains committed to bringing products and services to the brachytherapy market.

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.